Information about the novel coronavirus (the virus that causes COVID-19) is constantly evolving. We will refresh our novel coronavirus content periodically based on newly published peer-reviewed findings to which we have access. For the most reliable and up-to-date information, please visit the CDC website or the WHO’s advice for the public.
Since the new coronavirus disease 2019 (COVID-19) began in Wuhan, China, it has become a global pandemic affecting more than 24 million people in the United States and over 96 million people worldwide (as of Jan. 11, 2021) (ArcGis, 2021). Contributing to this spread is the fact that it’s possible to transmit the virus to others even if you don’t have any (or only have mild) symptoms. According to the Centers for Disease Control and Prevention (CDC), when symptoms of COVID-19 do occur, they usually appear 2–10 days after exposure to the virus and may include (CDC, 2020):
- There is no cure for the novel coronavirus at this time, but two vaccines have already received FDA emergency use approval for the prevention of COVID-19 .
- Remdesivir, an antiviral drug, has been approved by the FDA for the treatment of hospitalized patients with severe COVID-19 symptoms.
- Convalescent plasma has been used for other diseases and is being used as an experimental treatment for people with SARS-CoV-2.
- Other treatments being tested are immunomodulators, including dexamethasone, monoclonal antibodies (LY COV555, Actemra/RoActemra, Olumiant), and antibody cocktails like REGN-COV2.
- Fever or chills
- Muscle pain (myalgias)
- Shortness of breath (dyspnea)
- Coughing up mucus
- Sore throat
- Loss of smell (anosmia)
- Change in the sense of taste (dysgeusia)
- Stomach pain
- Runny nose
However, people over the age of 65 and those with chronic medical conditions like heart disease, diabetes, obesity, lung disease, liver problems, kidney disease, weak immune systems, or cancer may be at higher risk of developing severe symptoms, like acute respiratory distress syndrome (ARDS). These symptoms may require hospitalization, admission to the intensive care unit (ICU), intubation (mechanical ventilation), and can lead to death in some people.
Current COVID-19 treatments
Unfortunately, there is no cure currently approved for COVID-19 at this time. Two vaccines have, however, received emergency use authorization from the FDA for the prevention of coronavirus infection. While distribution is not widespread, governments are ramping up the distribution of the vaccines both in the United States and abroad.
In October 2020, the US Food and Drug Administration (FDA) approved an antiviral drug called remdesivir for the treatment of patients hospitalized with coronavirus. Antiviral drugs are medications that attack a virus after it has gotten into your body. Creating a new antiviral therapy to work against SARS-CoV-2 would take years. Instead, scientists turned to existing antiviral medications to see if any of them can help against COVID-19.
Remdesivir, an intravenous (IV) medication, was initially developed to help with other viruses, like the Ebola virus. This drug prevents virus particles from reproducing—if it can’t copy itself, then it can’t spread to other cells in the body.
One study showed that it might shorten hospital stays and improve symptoms in patients that required hospitalization (Beigel, 2020). Two other small studies showed the drug may offer some benefits when used for five days in patients hospitalized with coronavirus. At this time, remdesivir is the only medication to have received FDA approval for the treatment of COVID-19. Still, this treatment is not for everyone and is currently only recommended for adults and children over the age of 12 who require hospitalization (FDA, 2020).
In March and April 2020, the antimalarial drugs hydroxychloroquine and chloroquine were considered potential options for treatment. Early studies suggested that these medications may have antiviral action against SARS-CoV-2, the virus that causes COVID-19 (IDSA, 2020).
However, investigations later showed that there is an increased risk of heart rhythm problems and death in people given hydroxychloroquine and chloroquine. For this reason, the U.S. Food and Drug Administration (FDA) recommends that anyone given these medications for COVID-19 be kept under close medical supervision (e.g. part of a clinical trial) due to safety concerns and potential toxicity (IDSA, 2020).
Another medication being tested is favipiravir, an oral antiviral drug used to treat influenza (flu) in Japan. Recently, clinical trials have begun to see if favipiravir can be used to treat COVID-19 patients who are not hospitalized and have mild to moderate disease (Stanford, 2020). It is too early to tell if this drug will become part of the treatment arsenal.
Convalescent plasma is blood plasma taken from people who have recovered from SARS-CoV-2 infection. This plasma may contain antibodies against the virus. A plasma transfusion into a patient with a severe COVID-19 infection could help them fight off the disease quicker and more effectively, especially if done early. While convalescent plasma has been used in the past to treat other conditions (like the 2003 SARS-CoV epidemic, the 2009–2010 H1N1 influenza virus pandemic, and the 2012 MERS-CoV epidemic), its use for SARS-CoV-2 is still considered experimental. The National Institutes of Health state that there is not enough information to recommend for or against the use of convalescent plasma (NIH, 2020).
Immunomodulators are medicines used to normalize the immune system. COVID-19 can cause your body to react with an increased immune system response that leads to severe symptoms and can damage your lungs and other organs. Scientists investigating whether drugs that help regulate the immune response may protect against severe COVID-19 symptoms.
Dexamethasone is a corticosteroid with potent anti-inflammatory properties. A large clinical trial (over 6,000 participants) found that dexamethasone decreased mortality in hospitalized patients who were on mechanical ventilation (NIH, 2020). The current recommendation is that dexamethasone should be reserved for people who are intubated or who require supplemental oxygen during their hospitalization for COVID-19 (NIH, 2020). Corticosteroids are not benign medications—they should be used with caution and only under the supervision of your healthcare provider. With some viruses, corticosteroids can worsen the outcome. Dexamethasone should not be given to people who do not need oxygen support (NIH, 2020)
Monoclonal antibodies are drugs that attack a pathogen or target a specific step in the inflammation pathway. LY Cov555 is one monoclonal antibody medication being tested in people with early COVID-19 as well as in COVID-19 patients who require hospitalization. Trials are also looking at other monoclonal antibodies like tocilizumab (brand name Actemra/RoActemra), sarilumab, and siltuximab (interleukin-6 inhibitors) (UpToDate, 2020). At the moment, not enough evidence exists to recommend for or against the use of these drugs for COVID-19 treatment. Baricitinib (brand name Olumiant), an immunomodulator that works against Janus kinase (another part of the inflammation pathway), is currently not recommended for use against COVID-19 unless it is part of a clinical trial (NIH, 2020).
Lastly, Regeneron has an antibody “cocktail” REGN-COV2: a mixture of two human antibodies that are derived from the blood of people who recovered from a COVID-19 infection. By combining antibodies, the hope is that REGN-COV2 will be more effective at targeting and neutralizing the virus than single antibody therapies. The trial is expected to last through June 2021.
Most people have heard of using vitamin C and zinc supplements to fight the common cold, so it is no surprise that people are trying to use them against COVID-19. Vitamin C has antioxidant and anti-inflammatory properties. Zinc negatively affects the ability of some viruses to copy themselves. Unfortunately, there is not enough data to recommend for or against using vitamin C or zinc supplements for COVID-19 treatment (NIH, 2020). You should not use higher than recommended doses of zinc unless you are being monitored as part of a clinical trial (NIH, 2020). Vitamin D is another supplement of interest—given that immune system cells express it, vitamin D may play a role in regulating the immune response. The research is ongoing, but at the moment, there is not enough evidence to support or recommend against using vitamin D for COVID-19 treatment (NIH, 2020).
Roman Daily—Multivitamin for Men
Our team of in-house doctors created Roman Daily to target common nutrition gaps in men with scientifically backed ingredients and dosages.Learn more
What does this all mean?
We still do not have cure for COVID-19, but scientists are learning more about the disease every day, and researchers are actively trying to develop and test medications and vaccines. In October of 2020, the FDA approved an antiviral medication called remdesivir for the treatment of COVID-19. While this treatment isn’t for everyone, it was shown in certain clinical trials to shorten hospitalization time in severely ill patients (FDA, 2020). In December 2020, the first two vaccines received emergency use authorization from the FDA and are currently being distributed both in the United States and abroad.
The vaccine will not initially be available to everyone. Instead, frontline workers (healthcare professionals, etc.) and people at high risk of serious infection will be able to get the vaccine first, and younger, healthier individuals may have to wait. In the meantime, there are some steps you can take to help keep yourself and your loved ones safe. Whenever possible, avoid contact with others. When you are out, remember to practice social distancing—avoid large groups of people and stay at least six feet away from others. Wear a face mask in public and wash your hands frequently—especially before eating and touching your face.
If you are exposed to a person who has been diagnosed with coronavirus, it’s important to self-quarantine for 10 days. If you yourself test positive for COVID-19, the CDC guidelines recommend self-isolating, including from members of your own household if possible. Ten days after the appearance of your first symptoms, if you have been fever-free without fever-lowering medication for at least 24 hours, it becomes unlikely that you might infect another person (CDC, 2020).